NCT02036879View on ClinicalTrials.gov

Gender Disparity and Hormones in Cystic Fibrosis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Cystic Fibrosis (CF)
Interventions
DRUG

Loestrin (norethindrone acetate and ethinyl estradiol)

This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.

Trial Locations (2)

75207

Children's Medical Center, Dallas

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT02036879 - Gender Disparity and Hormones in Cystic Fibrosis | Biotech Hunter | Biotech Hunter